Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCRX logo BCRX
Upturn stock ratingUpturn stock rating
BCRX logo

BioCryst Pharmaceuticals Inc (BCRX)

Upturn stock ratingUpturn stock rating
$9.39
Delayed price
Profit since last BUY9.06%
upturn advisory
Consider higher Upturn Star rating
BUY since 11 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: BCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -5.43%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.94B USD
Price to earnings Ratio -
1Y Target Price 15.27
Price to earnings Ratio -
1Y Target Price 15.27
Volume (30-day avg) 2904405
Beta 1.75
52 Weeks Range 4.03 - 9.50
Updated Date 02/21/2025
52 Weeks Range 4.03 - 9.50
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.61

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-02-24
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -30.01%
Operating Margin (TTM) 6.57%

Management Effectiveness

Return on Assets (TTM) -4.25%
Return on Equity (TTM) -1925.37%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2424099841
Price to Sales(TTM) 4.71
Enterprise Value 2424099841
Price to Sales(TTM) 4.71
Enterprise Value to Revenue 5.88
Enterprise Value to EBITDA -12.2
Shares Outstanding 207132992
Shares Floating 193262974
Shares Outstanding 207132992
Shares Floating 193262974
Percent Insiders 1.46
Percent Institutions 81.75

AI Summary

BioCryst Pharmaceuticals Inc. (BCRX): A Detailed Overview

Company Profile:

Detailed History and Background: BioCryst Pharmaceuticals Inc. (BCRX) is a clinical-stage biopharmaceutical company founded in 1986 and headquartered in Durham, North Carolina. The company focuses on identifying, developing, and commercializing novel small molecule drugs for the treatment of rare diseases.

Core Business Areas: BioCryst operates in the following therapeutic areas:

  • Hereditary Angioedema (HAE): The company's lead product, berotralstat (Orladeyo), is approved for the prevention of HAE attacks in adults and adolescents.
  • Influenza: BioCryst's peramivir (Rapivab) is a neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza in adults.
  • Other Rare Diseases: BioCryst is also developing BCX9930, an oral Factor XIIa inhibitor, for the treatment of HAE and other potential indications.

Leadership and Corporate Structure:

  • Robert A. King: Chairman and Chief Executive Officer
  • William Sheridan: President and Chief Operating Officer
  • Jon P. Stonehouse: Chief Financial Officer
  • Jon A. Stonehouse: Chief Medical Officer
  • I. Richmond Daniels: General Counsel and Secretary

Top Products and Market Share:

Top Products:

  • Orladeyo (berotralstat): This oral Factor XIIa inhibitor is approved for the prevention of HAE attacks in adults and adolescents in the United States and Europe. It is estimated to have a market share of approximately 20-25% of the global HAE market.
  • Rapivab (peramivir): This intravenous neuraminidase inhibitor is approved for the treatment of acute uncomplicated influenza in adults. Its market share is relatively small compared to other influenza treatments.

Market Share Comparison:

  • HAE market: BioCryst's Orladeyo faces competition from Takeda's Takhzyro and Cinryze. While Orladeyo has gained significant market share, it still trails behind Takhzyro, which is estimated to hold a market share of around 50%.
  • Influenza market: Rapivab competes with other neuraminidase inhibitors like Tamiflu and Xofluza. Its market share is significantly smaller due to limited use and intravenous administration route.

Total Addressable Market (TAM):

The global market for HAE treatments is estimated to be around USD 2.5 billion and is expected to grow at a CAGR of around 10%. The US market for influenza treatments is estimated to be around USD 4 billion and is expected to grow at a slower pace.

Financial Performance:

Recent Financial Performance:

BioCryst's recent financial performance has been marked by increasing revenue, driven by the launch of Orladeyo. However, the company is not yet profitable and continues to incur significant operating expenses related to research and development.

Key Financial Metrics (2022):

  • Revenue: USD 232.4 million
  • Net Income: USD (174.2) million
  • Gross Profit Margin: 86.3%
  • Earnings per Share (EPS): USD (2.08)

Cash Flow and Balance Sheet:

BioCryst has a strong cash position with over USD 500 million in cash and equivalents as of December 31, 2022. The company's balance sheet is relatively healthy, with low debt levels.

Dividends and Shareholder Returns:

Dividend History: BioCryst does not currently pay a dividend.

Shareholder Returns: Over the past year, BCRX stock has performed well, with a total return of over 50%. However, over the past 5 and 10 years, shareholder returns have been negative due to the company's early-stage development and lack of profitability.

Growth Trajectory:

BioCryst's future growth is primarily dependent on the success of Orladeyo in the HAE market. The company is also exploring potential new indications for BCX9930, which could further drive growth.

Recent Product Launches:

  • Orladeyo: Launched in the US in December 2020 and in Europe in March 2021.
  • BCX9930: Phase 3 clinical trials ongoing for HAE prophylaxis.

Market Dynamics:

The HAE and influenza markets are both characterized by ongoing innovation and competition. New therapies with improved efficacy and safety profiles are constantly emerging. BioCryst needs to continue to innovate and differentiate its products to maintain market share.

Competitors:

Key HAE Competitors:

  • Takeda (TAK): Takhzyro
  • Shire (Shire): Cinryze
  • CSL Behring (CSL): Haegarda

Key Influenza Competitors:

  • Roche (RHHBY): Tamiflu
  • Genentech (RHHBY): Xofluza

Recent Acquisitions (past 3 years):

  • 2020: Acquired the global commercial rights to Orladeyo from Alnylam Pharmaceuticals.

This acquisition was a significant milestone for BioCryst, as it provided the company with full control over the commercialization of its lead product and expanded its global reach.

AI-Based Fundamental Rating:

AI Rating: 7/10

Justification: BioCryst has a promising product portfolio with Orladeyo leading the way in the HAE market. The company has a strong cash position and a healthy balance sheet. However, the company is not yet profitable and faces intense competition. BioCryst's future success will depend on its ability to expand Orladeyo's market share, successfully develop BCX9930, and navigate the evolving competitive landscape.

Sources and Disclaimers:

Sources:

  • BioCryst Pharmaceuticals Inc. website
  • SEC filings
  • Market research reports

Disclaimer:

This information is provided for general knowledge and informational purposes only, and does not constitute investment advice. It is essential to conduct thorough research and consult with financial professionals before making any investment decisions.

About BioCryst Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Durham, NC, United States
IPO Launch date 1994-03-03
CEO, President & Executive Director Mr. Jon P. Stonehouse
Sector Healthcare
Industry Biotechnology
Full time employees 536
Full time employees 536

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​